$HELP News

Cybin (HELP) Gets A Fresh Look On Trial Progress And CEO Change

Cybin (CYBN) Stock Sees Fair Value Lift As Sector Research Supports Growth Assumptions

TD Cowen Maintains Buy on Helus Pharma, Raises Price Target to $62

Cybin (HELP) Names New CEO, Is The Stock Still Cheap?

Cybin (HELP) Is Up 33.1% After Hiring Helus Veteran Michael Halstead As CEO – Has The Bull Case Changed?

Cybin (CYBN) Stock Fair Value Moves Lower As Analysts Rework Psychedelic Sector Assumptions

Cybin (HELP) Is Up 6.2% After Advancing HLP003 To Phase 3 And Raising US$50 Million

Is Cybin D/B/A Helus Pharma (HELP) Stock a Psychedelic Medicine Opportunity Ahead of HLP003 Trial Results?

HC Wainwright & Co. Maintains Buy on Helus Pharma, Lowers Price Target to $70

Helus Pharma Prices Underwritten Offering Of 10.3M Shares At $4.85 Per Share; Announces That Enrollment In The APPROACH Phase 3 Clinical Trial Of HLP003 For Adjunctive Treatment Of Major Depressive Disorder Is Progressing As Planned, Surpassing 86% Enrollment

Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade)

Helus Pharma CEO Michael Cola Stepping Down, Effective Immediately; Executive Chairman Eric So Appointed Interim CEO

TD Cowen Initiates Coverage On Helus Pharma with Buy Rating, Announces Price Target of $8

Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder - Slideshow

Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript

HC Wainwright & Co. Maintains Buy on Helus Pharma, Raises Price Target to $95

HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience

Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise

Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth Drivers

Helus Pharma shares are trading higher after the company announced publication in Nature Medicine of results from a Phase 2a clinical trial evaluating SPL026, in major depressive disorder.